TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2680158
Drug: All aspirin
Normalized name: CAREALL Aspirin 81mg Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All aspirin groups for grafts to vessels ≤ 2.0 mm
Study: 2680158
Drug: All aspirin
Normalized name: CAREALL Aspirin 81mg Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: All aspirin groups for grafts to vessels > 2.0 mm
Study: 30282861
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g butter (B10)
Study: 30282861
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g butter (B20)
Study: 30282861
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g butter (B40)
Study: 30282861
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g butter (control)
Study: 26440437
Drug: IV tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tramadol (2 mg/kg, 3 mL)
Study: 26440437
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration with tramadol (2 mg/kg, 3 mL)
Study: 18544622
Drug: 1,500 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 IU daily
Study: 18544622
Drug: 10,500 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,500 IU once weekly
Study: 15872124
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg plus metoclopramide 10 mg iv
Study: 15872124
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg iv
Study: 15385009
Drug: Early intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intravenous placement (30 seconds after loss of lid reflex)
Study: 15385009
Drug: Late intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late intravenous placement (120 seconds after loss of lid reflex)
Study: 10073791
Drug: Niacin and
Normalized name: My Favorite Niacin and Inositol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin and etofibrate combination
Study: 394281
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltarol) 25 mg t.d.s. for 2 weeks
Study: 394281
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg t.d.s. for 2 weeks
Study: 30107043
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg, twice daily for 52 weeks
Study: 30107043
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 52 weeks
Study: 25231565
Drug: Active bioresonance
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active bioresonance therapy
Study: 10380428
Drug: Antifungal drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal drugs
Study: 6751374
Drug: Topical benzimidazole
Normalized name: benzimidazole
DrugBank: Benzimidazole (DB02962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzimidazole sunscreen cream
Study: 28126898
Drug: Atosiban (6.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (6.75 mg)
Study: 28126898
Drug: Fenoterol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (40 μg)
Study: 26820158
Drug: Vitamin E,
Normalized name: GRx Vitamin E, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin E, C, A, and N-acetylcysteine daily (treatment group)
Study: 17466492
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 3 mg
Study: 17265397
Drug: Engineered sharps
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engineered sharps injury prevention device (ESIPD) - intravenous (IV) catheter stylet with a safety-engineered feature (retractable protection shield)
Study: 12413985
Drug: Tibolone, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone, 2.5 mg/d for 4 months
Study: 10220653
Drug: Neo-Temp luting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-Temp luting agent
Study: 10220653
Drug: Temp Bond
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temp Bond luting agent
Study: 10220653
Drug: Provilink luting
Normalized name: MULTIVIT/OPHTH AREDS2/LUTE/ZEAX CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provilink luting agent
Study: 27015966
Drug: Panic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic and Smoking Reduction Treatment (PSRT) + d-cycloserine (DCS)
Study: 27015966
Drug: Panic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panic and Smoking Reduction Treatment (PSRT) + placebo
Study: 22622911
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with local anesthetic and steroids
Study: 22622911
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections (unspecified)
Study: 16075363
Drug: Adjuvant oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oral clodronate (1.6 g/day) for 3 years
Study: 10189133
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 10 mg twice daily
Study: 10189133
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) plus octreotide 150 microg (subcutaneously thrice daily)
Study: 1955654
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg every 12 hours for 3 days (first dose 800 mg)
Study: 6814284
Drug: Intranasal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunotherapy with Glu‐Rye (10-week course)
Study: 6814284
Drug: Intranasal immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal immunotherapy with Glu‐Rye
Study: 19139439
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (15 weeks) followed by surgery (arm A)
Study: 19139439
Drug: Chemotherapy (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B)
Study: 9564208
Drug: Fluoxetine (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (N = 8)
Study: 9564208
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and Placebo (combined sample of 17 cocaine-abusing depressed alcoholics)
Study: 363434
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release oxprenolol (SRO) once daily
Study: 363434
Drug: Conventional oxprenolol
Normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional oxprenolol (CO) once daily
Study: 363434
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of SRO
Study: 363434
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of SRO
Study: 17719468
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg once daily for 6 months followed by 6 months of single-blind Val in both groups
Study: 15064638
Drug: Empirical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical therapy based on baseline culture data
Study: 11478829
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (0.45 g kg(‐1)day(‐1)) for eight weeks
Study: 7798804
Drug: Plasminogen activation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasminogen activation using streptokinase in blood suspensions of diabetic patients
Study: 7798804
Drug: Plasminogen activation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasminogen activation using streptokinase in blood suspensions of healthy subjects
Study: 31331583
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of Panax Ginseng twice daily for four weeks
Study: 28364587
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBGT) for OCD, involving family members in two sessions, 12 sessions total.
Study: 16408442
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group treated as same as adult patients with diabetes mellitus
Study: 15329366
Drug: saquinavir/ritonavir 1000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir/ritonavir 1000/100 mg twice-daily
Study: 15329366
Drug: saquinavir/ritonavir 2000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir/ritonavir 2000/100 mg once-daily
Study: 15329366
Drug: saquinavir/ritonavir 1600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: saquinavir/ritonavir 1600/100 mg once-daily
Study: 10934984
Drug: Various β-Blockers
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various β-Blockers
Study: 1286547
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg once daily for 4 weeks)
Study: 4036846
Drug: High P/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: High P/S ratio diet with high cholesterol (1,000 mg/day)
Study: 4036846
Drug: High P/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: High P/S ratio diet with low cholesterol (300 mg/day)
Study: 4036846
Drug: Low P/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low P/S ratio diet with high cholesterol (1,000 mg/day)
Study: 4036846
Drug: Low P/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low P/S ratio diet with low cholesterol (300 mg/day)
Study: 30774388
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg every 4 weeks (Q4W)
Study: 30661249
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg every 8 weeks (Q8W)
Study: 22184611
Drug: Ropivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (20 mL of different concentrations)
Study: 20705980
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tubewells, Clorin, and hygiene promotion
Study: 2766870
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis with 2 x 2 g ceftriaxone (Rocephin)
Study: 26041028
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (1000 mg)
Study: 23853552
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly iron‐folic acid (IFA)
Study: 23853552
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly multiple micronutrient (MMN)
Study: 23853552
Drug: Daily iron‐folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron‐folic acid (IFA)
Study: 21160152
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (Instillagel®) during GIS
Study: 21160152
Drug: Gel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel without lidocaine (Endosgel®) during GIS
Study: 21160152
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (Instillagel®) during hysteroscopy
Study: 21160152
Drug: Gel without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gel without lidocaine (Endosgel®) during hysteroscopy
Study: 19557003
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of angiotensin‐II receptor blocker (ARB)
Study: 19557003
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of ARB plus calcium channel blocker (amlodipine)
Study: 16485881
Drug: 0.5% fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% fluorouracil cream (FC) applied once daily for 7 days
Study: 16485881
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (VC) applied once daily for 7 days
Study: 8284632
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g four times daily for 3 weeks)
Study: 3126024
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy recruitment
Study: 25212062
Drug: Obesity prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obesity prevention intervention programme delivered by teachers promoting physical activity and healthy eating; specific dosage and duration not mentioned.
Study: 17643572
Drug: Atorvastatin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin alone (single therapy), placebos for ER-niacin and colesevelam
Study: 17643572
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus ER-niacin (2 g/d), placebo for colesevelam (double therapy)
Study: 17643572
Drug: Atorvastatin, ER-niacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, ER-niacin, plus colesevelam (3.8 g/d) (triple therapy)
Study: 17643572
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for ER-niacin and colesevelam (single therapy)
Study: 9260213
Drug: Ice water
Normalized name: CVS Electrolyte Solution with Zinc (Rice Water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice water ingestion (250 ml of 0‐4 degrees C)
Study: 9260213
Drug: Warm water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm water ingestion (250 ml of 25 degrees C)
Study: 30354231
Drug: Heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme arginate 1 mg/kg
Study: 30354231
Drug: Heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme arginate 3 mg/kg
Study: 30354231
Drug: Heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme arginate infusion
Study: 24606105
Drug: Usual anti-hyperglycemic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual anti-hyperglycemic therapy
Study: 22915615
Drug: Tumour necrosis
Normalized name: Tumour necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour necrosis factor inhibitor
Study: 16948965
Drug: Topical salicylate
Normalized name: salicylic acid Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical salicylate
Study: 16948965
Drug: Er:Yag laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:Yag laser therapies
Study: 8795326
Drug: Midazolam (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.04 mg.kg‐1) and Alfentanil (10 micrograms.kg‐1) followed by Propofol (1.25 mg.kg‐1)
Study: 8795326
Drug: Alfentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (10 micrograms.kg‐1) followed by Propofol (1.25 mg.kg‐1)
Study: 8795326
Drug: Propofol only
Normalized name: Propofol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol only (2.5 mg.kg‐1)
Study: 1621413
Drug: Intranasal aerosol
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal aerosol administration of quadrivalent inactivated split influenza vaccine
Study: 1621413
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of quadrivalent inactivated split influenza vaccine
Study: 1621413
Drug: Saline intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intranasal administration
Study: 26866433
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg after tracheal intubation and ondansetron 4 mg during skin closure
Study: 24419137
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MSC and LDCT
Study: 22429268
Drug: 5-fluorouracil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil plus bevacizumab (1.25 mg/0.05 mL)
Study: 22429268
Drug: 5-fluorouracil only
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil only (7.5 mg/0.15 mL)
Study: 17233688
Drug: Psychiatric intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric intervention (treatment study)
Study: 10971683
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (one tablet qds) + amoxicillin (500 mg qds) + metronidazole (400 mg tds)
Study: 10971683
Drug: Bismuth subnitrate
Normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subnitrate (two tablets tds) + amoxicillin (500 mg qds) + metronidazole (400 mg tds)
Study: 10971683
Drug: Placebo bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bismuth (two tablets tds) + amoxicillin (500 mg qds) + metronidazole (400 mg tds)
Study: 10971683
Drug: Bismuth subnitrate
Normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth subnitrate (two tablets tds) + placebo antibiotics
Study: 8967617
Drug: Pentaglobin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin therapy (Group 1)
Study: 8967617
Drug: No immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunoglobulin therapy (Group 2)
Study: 1474536
Drug: Indomethacin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (75 mg/day)
Study: 6439566
Drug: SUL (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUL (1 mg/kg i.m.)
Study: 6439566
Drug: SUL +
Normalized name: dihydralazine sul hemipenthy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUL + PL (2 ml saline i.v.)
Study: 6439566
Drug: SUL +
Normalized name: dihydralazine sul hemipenthy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUL + TRH (200 mcg i.v.)
Study: 6439566
Drug: TRH (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH (200 mcg i.v.)
Study: 16825847
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (once a day for 3 days, 30-60 minutes per day)
Study: 8675168
Drug: UDCA (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (15 mg/kg body weight daily) plus taurine (30 mg/kg body weight daily)
Study: 30355117
Drug: IVT+MT (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVT+MT (in patients without anticoagulant medication before stroke onset)
Study: 24884885
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of folic acid (FA) daily
Study: 24884885
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg of folic acid (FA) daily
Study: 23157895
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment with naltrexone (22-week comprehensive intervention)
Study: 19378423
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (400 mg vitamin C and 180 mg vitamin E d(‐1) and 200 mg BiO‐Quinon Q10 d(‐1))
Study: 15339559
Drug: Jianpi Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi Huoxue Jiedu (JPHXJD) prescription combined with chemotherapy
Study: 10229744
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Verapamil and Trandolapril
Study: 8722437
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (amlodipine)
Study: 8722437
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor (lisinopril)
Study: 8722437
Drug: HMG CoA
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG CoA reductase inhibitor (pravastatin)
Study: 27955918
Drug: Dexmedetomidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (50 µg) added to lidocaine (9.5 mL) and ropivacaine (10 mL)
Study: 27955918
Drug: Saline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.5 mL) added to lidocaine (9.5 mL) and ropivacaine (10 mL)
Study: 17453654
Drug: Protocolized pharmacotherapy
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized pharmacotherapy with nortriptyline
Study: 17453654
Drug: Protocolized pharmacotherapy
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized pharmacotherapy with nortriptyline-plus-lithium
Study: 15189389
Drug: Aspirin, beta-blockers,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, beta-blockers, and angiotensin converting enzyme inhibitors
Study: 11699982
Drug: Antimicrobial agents
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents for caries management
Study: 9688168
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil capsules containing 1.5 g DHA
Study: 9688168
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil capsules containing 97% soybean oil plus 3% of another fish oil